Drug-Induced Hyperthyroidism in a Previously Hypothyroid Patient

Step 1: Identify the Causative Drug

• Tietz Textbook of Laboratory Medicine, p. block25: Drug-induced hyperthyroidism includes iodine-containing drugs (amiodarone), radiographic contrast agents, and iodine itself.

Step 2: Immediate General Measures

1. Hold or reduce levothyroxine - the patient is now getting exogenous thyroid hormone on top of drug-induced overproduction; the LT4 dose must be reduced or stopped.
2. Beta-blocker for symptom control - atenolol 25-100 mg/day (or propranolol) relieves palpitations, tremor, tachycardia, and anxiety while definitive treatment takes effect. The dose is adjusted to clinical response and gradually weaned as thyroid function normalizes.
   • Washington Manual of Medical Therapeutics, p. 5563

Step 3: Drug-Specific Treatment

A. Amiodarone-Induced Thyrotoxicosis (AIT) - Most Complex

• Antithyroid drugs (ATDs) - methimazole 20-40 mg/day is first-line
• Perchlorate (up to 1 g/day) can be added in resistant cases to block iodine uptake
• Stop amiodarone if clinically feasible (cardiac risk-benefit decision); note: stopping it does NOT rapidly improve thyrotoxicosis due to amiodarone's 40-55 day half-life
• Braunwald's Heart Disease, p. 1108-1110

• ATDs are ineffective (no active synthesis occurring)
• First-line: oral glucocorticoids - prednisone typically 30-40 mg/day, tapered over weeks
• Amiodarone can be continued if life-threatening arrhythmia requires it (weighed on a case-by-case basis)
• Braunwald's Heart Disease, p. 1121-1123; Mulholland & Greenfield's Surgery, p. 179-183

• Treat both simultaneously: methimazole 10-20 mg twice daily PLUS prednisone 30-40 mg/day
• Goldman-Cecil Medicine, p. 3239
• Close follow-up of TFTs; titrate down as euthyroidism is achieved

• Total thyroidectomy can rapidly reverse hyperthyroidism, especially when cardiovascular function is deteriorating; no cases of thyroid storm from surgery reported when beta-blocked preoperatively
• RAI is generally not effective in AIT due to low iodine uptake; restore euthyroidism first if attempted
• Braunwald's Heart Disease, p. 1112-1116

B. Iodine/Contrast-Induced Hyperthyroidism (Jod-Basedow)

• Thionamides (methimazole or PTU) + atenolol until euthyroid
• Lithium is the preferred agent for blocking new hormone synthesis in truly iodine-allergic patients (since it also blocks iodine release without needing iodine-related mechanisms)
• Rosen's Emergency Medicine, p. 197; Washington Manual, p. 5581
• RAIU will be very low; RAI therapy is NOT an option during the high-iodine state (must wait weeks to months)

C. Immune Checkpoint Inhibitors (ICI-Induced Thyroiditis)

• Often presents as a transient hyperthyroid phase followed by permanent hypothyroidism
• Treatment: atenolol 25-50 mg/day for symptom control during the hyperthyroid phase (typically 4-6 weeks)
• Do NOT routinely give thionamides (not production-mediated)
• The hypothyroid phase is generally permanent - these patients will need lifelong levothyroxine
• If hyperthyroidism does not remit after 4-6 weeks, consider evolving Graves disease and treat accordingly
• Goldman-Cecil Medicine, p. 3238

D. Lithium-Induced Hyperthyroidism

• Stop lithium (in consultation with psychiatry, with a transition plan)
• Treat with thionamides if TSH remains suppressed after discontinuation
• Rosen's Emergency Medicine, p. 206

E. Interferon / IL-2 / Other Immunomodulators

• Discontinuation of the offending drug is not always mandatory - depends on oncologic or disease necessity
• Treat based on the type of thyroid reaction (thyroiditis pattern = beta-blocker; production pattern = thionamides)
• Rosen's Emergency Medicine, p. 206

Step 4: Special Considerations for Previously Hypothyroid Patients

1. Stop or significantly reduce levothyroxine - continuing full replacement doses accelerates the thyrotoxicosis.
2. Monitor TFTs closely (every 2-4 weeks initially) - these patients are at risk for swinging back to hypothyroidism, especially after destructive thyroiditis (ICIs, AIT-2) resolves.
3. Post-resolution levothyroxine restart: Once the drug-induced hyperthyroid phase resolves:
   • Restart LT4 at a lower dose than pre-event (the underlying cause of hypothyroidism may have changed)
   • After ICI thyroiditis: permanent hypothyroidism is common; restart LT4 using weight-based dosing (1.6 mcg/kg/day) - Goldman-Cecil Medicine, p. 3238
4. Levothyroxine-on-amiodarone TSH target: In amiodarone-induced hypothyroidism, TSH targets are balanced against arrhythmia risk - slight TSH suppression may be tolerated - Braunwald's Heart Disease, p. 1101

Summary Table

• Goldman-Cecil Medicine International Edition, pp. 3231-3239
• Braunwald's Heart Disease, pp. 1095-1129
• Washington Manual of Medical Therapeutics, pp. 5561-5581
• Katzung's Basic and Clinical Pharmacology 16e, pp. 1289-1292
• Rosen's Emergency Medicine, pp. 197-206
• Mulholland & Greenfield's Surgery 7e, pp. 179-183

Antithyroid Drugs and Renal Safety

The Short Answer

Pharmacokinetics in Renal Disease

• Goodman & Gilman's Pharmacological Basis of Therapeutics, Table 47-5

Drug-by-Drug Analysis

1. Methimazole (Preferred Agent Overall)

• Primarily metabolized hepatically; 65-70% of a dose recovered in urine over 48 hours, but mostly as metabolites
• Only 10-15% excreted unchanged in urine
• Renal excretion is the primary elimination route for its metabolites
• Impaired renal function can result in elevated plasma concentrations of metabolites, but clinical significance is unclear

• No formal dose adjustment required per regulatory labeling or major guidelines
• StatPearls/NCBI: "Renal impairment does not affect methimazole clearance. There are neither specific guidelines nor a need for dosage adjustments for patients with renal impairment"
• Canadian labeling takes a more conservative stance: "Keep dose as low as possible; careful individual dose adjustment under close monitoring is recommended due to lack of pharmacokinetic data in renal impairment"
• Monitor TSH and free T4 regularly; titrate to clinical response
• Methimazole is the preferred thionamide in CKD for most indications given its once-daily dosing, lower hepatotoxicity risk, and established use

• Agranulocytosis (0.1-0.5%) - difficult to distinguish from infection-related leukopenia in CKD/dialysis patients; baseline CBC recommended
• ANCA-associated vasculitis is a rare but serious adverse effect - particularly relevant in CKD since it can cause additional renal injury; long-term use requires monitoring of urinalysis and renal function

2. Propylthiouracil (PTU)

• Rapidly absorbed; majority excreted within 24 hours by the kidney as the inactive glucuronide
• High plasma protein binding (~75%) limits dialyzability
• Less than 10% excreted unchanged in urine
• PDR labeling: "No dosage adjustment is needed" for renal impairment

• Metabolism is normal even in severe kidney disease (Goodman & Gilman)
• Renally cleared but largely as inactive metabolite, so accumulation risk is low
• No dose reduction needed based on GFR

• PTU carries a black box warning for severe, potentially fatal hepatotoxicity (fulminant hepatic necrosis) - this restricts its use to specific indications: first trimester pregnancy, thyroid storm, and methimazole intolerance
• PTU-induced ANCA vasculitis (MPO-ANCA positive) can cause renal disease including pauci-immune crescentic glomerulonephritis - a serious concern if used long-term in a patient who already has CKD
• More frequent dosing (every 6-8 hours) reduces adherence
• Katzung's Basic & Clinical Pharmacology 16e, pp. 1038-1048

Important CKD-Specific Consideration: Hyperthyroidism Masks Renal Function

• Hyperthyroidism creates a hyperdynamic state that artificially increases renal blood flow and GFR, lowering serum creatinine and BUN
• When hyperthyroidism is treated and euthyroidism is restored, GFR falls - this can unmask pre-existing CKD or worsen known CKD
• The drop in GFR is not caused by the antithyroid drug itself, but by correction of the hyperthyroid-driven hyperfiltration
• Clinical implication: In a patient with known CKD or borderline renal function, start antithyroid therapy at a lower dose, restore euthyroidism gradually, and monitor renal function (creatinine, BUN, electrolytes) closely during the first 4-8 weeks of treatment

Comparison with Other Antithyroid Options in CKD

Summary Recommendation

1. Use methimazole as first-line - no dose adjustment required, once-daily dosing
2. Start at the lower end of the dose range (5-10 mg/day for mild-moderate disease), titrate to TSH/fT4
3. Monitor renal function at baseline and during treatment (GFR may fall as thyroid function normalizes)
4. Watch for ANCA vasculitis (urinalysis + renal function) especially on long-term therapy
5. Use PTU only in the usual restricted indications; it is also renally safe but carries higher toxicity risk
6. Avoid lithium and use perchlorate cautiously or not at all in significant CKD

• Goodman & Gilman's Pharmacological Basis of Therapeutics, Table 47-5 (pharmacokinetics in severe kidney disease)
• Katzung's Basic & Clinical Pharmacology 16e, pp. 1036-1048
• StatPearls - Methimazole (NCBI Bookshelf, NBK545223)
• PDR Drug Summary - Propylthiouracil
• Canadian Methimazole Prescribing Information (MAR-Methimazole)

Renal-Safe Antidiabetic Drugs

Quick Reference: CKD Stages

Class-by-Class Analysis

1. Insulin - SAFE (with dose reduction)

• Can be used at all stages of CKD, including dialysis
• The kidney contributes ~30-40% of insulin degradation and clearance; as GFR falls, insulin half-life increases and requirements decrease - hypoglycemia risk rises
• Key principle: reduce insulin doses as CKD progresses; frequent blood glucose monitoring is mandatory
• Goldman-Cecil Medicine: "as GFR declines, insulin requirements may decrease owing to reduced insulin degradation and clearance by the failing kidney"
• Preferred agent in ESRD/dialysis - most titrable, no renal contraindication
• Short-acting (regular, lispro, aspart) preferred; avoid pre-mixed formulations in advanced CKD due to unpredictable effect duration

2. Metformin (Biguanide) - CONDITIONALLY SAFE

• Risk: lactic acidosis (accumulates in renal failure; 3/100,000 patient-years risk)
• Guidance:
  • eGFR ≥45: full dose (up to 2000-2500 mg/day)
  • eGFR 30-44: reduce dose to 500 mg twice daily; use with caution
  • eGFR <30: stop - contraindicated
• Hold 48 hours after IV contrast, surgery, or any acute illness that could transiently impair renal function
• Washington Manual of Medical Therapeutics: "Reduce dose to 500 mg 2x daily if eGFR <45 mL/min/1.73 m²; stop if eGFR <30 mL/min/1.73 m²"
• Despite the restriction, metformin has cardiovascular benefits and should be continued as long as safely tolerated

3. DPP-4 Inhibitors (Gliptins) - MOSTLY SAFE (with dose adjustment)

• Washington Manual: "Linagliptin - No [renal dosing necessary]"

4. SGLT2 Inhibitors - CONDITIONALLY SAFE (limited by efficacy at low GFR, but reno-protective above threshold)

• CREDENCE: Canagliflozin reduced ESKD, doubling of serum creatinine, and renal death by 34% in T2DM with stage 2-3 CKD
• EMPA-REG: Empagliflozin reduced CV death by 38%, HF hospitalization by 35%
• DECLARE-TIMI 58: Dapagliflozin reduced composite renal endpoint by 24%
• Comprehensive Clinical Nephrology 7e, Table 33.2

5. GLP-1 Receptor Agonists - MOSTLY SAFE

• Washington Manual of Medical Therapeutics, pp. 4761-4785

6. Thiazolidinediones (TZDs) - SAFE BUT CAUTION

• Pioglitazone: No renal dose adjustment needed; renally safe
• However, causes fluid retention and edema - worsens in CKD context, can precipitate or worsen heart failure (avoid in NYHA III/IV HF)
• Can be used in CKD including advanced stages, but the fluid retention risk limits practical use
• Washington Manual: "Pioglitazone - No [renal dosing necessary]"
• Caution in advanced age, pre-existing edema, renal failure, and patients already on insulin

7. Sulfonylureas - USE WITH CAUTION / MOSTLY AVOID

• Goldman-Cecil: "use of sulfonylureas is contraindicated in patients with stage 3b CKD or worse (GFR <45)"
• If a sulfonylurea must be used, gliclazide or glipizide are the preferred options

8. Meglitinides - CONDITIONALLY SAFE

9. Alpha-Glucosidase Inhibitors - AVOID IN MODERATE-SEVERE CKD

• Acarbose and Miglitol: Avoid if serum creatinine >2.0 mg/dL
• Drug and metabolites accumulate in renal failure; safety not established
• Voglibose: not renally excreted; data limited

10. Bile Acid Sequestrants / Dopamine Agonists - SAFE BUT NICHE

• Colesevelam: No renal dose adjustment; can be used in renal and hepatic disease; minor glucose-lowering effect
• Bromocriptine mesylate: No renal adjustment; limited glycemic efficacy

Summary Table: Preferred Agents by CKD Stage

The "Most Renal-Safe" Shortlist

1. Insulin - universal, fully titratable
2. Linagliptin - only DPP-4 inhibitor with no dose adjustment at any GFR
3. Semaglutide / Dulaglutide (injectable GLP-1) - no renal adjustment
4. Pioglitazone - no renal adjustment (watch fluid retention)
5. Gliclazide - safest sulfonylurea if one must be used

• Washington Manual of Medical Therapeutics, Table 23-5 (Noninsulin Medications for Diabetes), pp. 4676-4790
• Goldman-Cecil Medicine International Edition, pp. 3996-4005
• Comprehensive Clinical Nephrology 7e, Table 33.2 (SGLT2i trials in diabetic kidney disease)